Abivax

September 5, 2018September 5, 2018

Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial

News

Abivax‘s small, anti-inflammatory molecule ABX464 significantly increased clinical remission and mucosal healing over placebo in patients with moderate to severe active ulcerative colitis resistant to other therapies, top-line results from a ... Read more

January 8, 2018January 8, 2018

Belgium Approves Extension Trial of Abivax’s Ulcerative Colitis Therapy

News

Regulators in Belgium have approved Abivax’s request for a long-term extension of the company’s ongoing Phase 2a trial of ABX464 as a treatment for ulcerative colitis. It said it expects approvals from ... Read more

November 21, 2017

First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment

News

A first patient has been enrolled in a proof-of-concept clinical trial of ABX464 as a possible treatment for people with moderate-to-severe active ulcerative colitis, its developer, Abivax, announced in a press release. The patient ... Read more

September 25, 2017

France Is First EU Country to Give Abivax Go-ahead to Test ABX464 in Ulcerative Colitis

News

France has become the first European country to give Abivax a green light to start clinical trials of ABX464 as a treatment for moderate-to-severe active ulcerative colitis. The therapy candidate is already being tested ... Read more

July 19, 2017August 29, 2017

Scientists Study How Abivax’s Anti-Inflammatory Product ABX464 Works in IBD

Crohn's Disease, News

Researchers have gained new insights into how Abivax’s investigational product ABX464 works. The therapy is currently under investigation in Phase 2 trials in patients with inflammatory bowel disease (IBD). Findings of ... Read more